Tue.Dec 19, 2023

article thumbnail

How Patient Characteristics, SDOH, Impact CLL, SLL Treatment Backdrop

Drug Topics

Social determinants of health (SDOH), such as financial disparities or lack of insurance, create barriers to accessing breakthrough therapies like BTK inhibitors among patients with CLL and SLL.

Insurance 220
article thumbnail

Doxycycline for Treatment of Pneumococcal Infection Could Reduce Clostridioides difficile Infection

Pharmacy Times

Less than 1% of individuals developed Clostridioides difficile infection (CDI), but for those who previously had a CDI the year before, 12% developed a new infection.

160
160
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

U.S. government spent more on health care in 2022 than six countries with universal health care combined

STAT

American taxpayers footed the bill for at least $1.8 trillion in federal and state health care expenditures in 2022 — about 41% of the nearly $4.5 trillion in both public and private health care spending the U.S. recorded last year, according to the annual report released last week by the Centers for Medicare and Medicaid Services. On top of that $1.8 trillion, third-party programs, which are often government-funded, and public health programs accounted for another $600 billion in spendin

Insurance 145
article thumbnail

Few health plans have dedicated Alzheimer’s and dementia care management strategy: survey

Fierce Healthcare

Health plans and value-based care organizations are ill-prepared to help patients with Alzheimer’s Disease or related dementia. | Only a small fraction of health plans and value-based care organizations have a fully developed care management model for its enrollees with dementia or Alzheimer's, a new survey shows.

139
139
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Here are the worst biopharma CEOs of 2023

STAT

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023 , then Pfizer CEO Albert Bourla is, unfortunately, the worst. My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps , financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis.

144
144
article thumbnail

Expert Reflects on Trends, US Market of Biosimilars in 2023

Pharmacy Times

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, discusses the dynamic landscape of the biosimilars market, providing key insights into its current status and future projections.

132
132

More Trending

article thumbnail

Most doctors have not yet tried AI but are 'cautiously optimistic' about the benefits

Fierce Healthcare

The hype around healthcare artificial intelligence has reached a fever pitch but most doctors are holding back from trying it out in their medical practice, for now. | Among those who are holding off, doctors report lack of confidence in accuracy and a lack of integration or access through existing tools — as key obstacles to adoption.

135
135
article thumbnail

STAT+: Amy Abernethy to step down as Verily’s chief medical officer in latest departure from company

STAT

Amy Abernethy, the president of product development and chief medical officer at Verily, a health care spinout of search giant Alphabet, will leave the company at the end of the first quarter to start a nonprofit aimed at changing the way the health care system collects data. The company announced Abernethy’s move to employees on Tuesday. Both Verily and Abernethy insist the company is well-positioned to move toward her vision — that changing clinical research can speed the develop

139
139
article thumbnail

2024 Outlook: How tech, incentives could push measurement-based care in behavioral health

Fierce Healthcare

Imagine if a patient came to see a doctor for high blood pressure. | Imagine if a doctor measured a patient's blood pressure once on intake, and then never again, while continuing their treatment. While the idea of not having quantifiable data to measure outcomes in medical care seems absurd, that is most often the case in behavioral health. Could that soon change?

133
133
article thumbnail

FDA Approves Birch Triterpenes Topical Gel for Treatment for Adult, Pediatric Patients With JEB, DEB

Pharmacy Times

This approval makes birch triterpenes the first treatment for wounds associated with junctional epidermolysis bullosa to be approved by the FDA.

FDA 139
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Amid BioNTech legal fight, CureVac takes a loss as German court invalidates patent

Fierce Pharma

A German court has dealt the first blow against CureVac amid the company's heated COVID-19 vaccine patent fight with fellow German mRNA specialist BioNTech. | A German court has dealt the first blow against CureVac amid the company's heated COVID-19 vaccine patent fight with fellow German mRNA specialist BioNTech.

Vaccines 126
article thumbnail

FDA Grants Priority Review to New Biologics License Application for V116 Against Pneumococcal Disease

Pharmacy Times

If approved, V116 would offer significant improvements in safety and effectiveness for the prevention of pneumococcal disease.

FDA 145
article thumbnail

Roche, Novartis move Xolair closer to FDA finish line for food allergies

Fierce Pharma

On the market for two decades for asthma, Novartis and Roche’s Xolair is closing in on a new indication as a way for those with food allergies to avoid severe outcomes. | On the market for two decades for asthma, Novartis and Roche’s Xolair is closing in on a new indication as a way for those with food allergies to avoid severe outcomes. The agency granted a priority review to Roche's filing and plans to make a decision during the first quarter of next year.

FDA 124
article thumbnail

FDA Accepts BLA for Garadacimab as a Once-Monthly Treatment for Hereditary Angioedema

Pharmacy Times

Previously, garadacimab was granted an orphan drug designation as a therapy for hereditary angioedema by both the FDA and EMA.

FDA 143
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

2024 Outlook: Can GLP-1 patients stop taking the drug and keep weight off?

Fierce Healthcare

GLP-1 medications were one of the hottest topics in healthcare in 2023, and interest in the weight-loss medications is only expected to increase, which will likely result in different approaches fr | If 2023 was the year of shedding pounds with anti-obesity medications, weight loss companies wonder if 2024 is the year of tapering down drug usage while still keeping the weight off.

124
124
article thumbnail

Sanofi, AstraZeneca Will Release Additional Doses of Nirsevimab-Alip to Meet Unprecendented Demand

Drug Topics

In January 2024, Sanofi and AstraZenenca will release 230,000 additional doses of nirsevimab-alip, heeding guidance from the CDC to leverage all tools to increase immunizations against RSV.

article thumbnail

STAT+: Health care industry fights back against crackdowns on health data tracking

STAT

Wherever you go on the internet, trackers follow. These ubiquitous bits of code , invisibly embedded in most websites, are powerful tools that can reveal the pages you visit, the buttons you click, and the forms you fill to help advertisers tail and target you across the web. But put those trackers on a health care website, and they have the potential to leak sensitive medical information — a risk that, in the last year, has driven the Department of Health and Human Services and the Feder

Hospitals 117
article thumbnail

Study Identifies Risk Factors for Colorectal Cancer in Adults With T2D

Drug Topics

Study findings shed light on the disproportionate burden of type 2 diabetes (T2D) and colorectal cancer faced by individuals with low socioeconomic status and those of African American race.

98
article thumbnail

Jefferson Health, Lehigh Valley Health Network targeting $14B, 30-hospital merger

Fierce Healthcare

Philadelphia-based Jefferson Health and Allentown, Pennsylvania-based Lehigh Valley Health Network (LVHN) have taken the initial steps toward a $14 billion merger, the systems announced Tuesday.

Hospitals 115
article thumbnail

Biogen notches another Tecfidera patent win in Europe as officials revoke generic approvals

Fierce Pharma

Following a significant loss at the U.S. Supreme Court last October, Biogen’s Tecfidera patent odyssey continues to spin in the company’s favor overseas. | The European Commission has revoked marketing authorizations for generic versions of Biogen's multiple sclerosis med Tecfidera, also known as dimethyl fumarate, that are owned by Accord, Mylan, Neuraxpharm, Polpharma and Teva.

115
115
article thumbnail

Why digital therapeutics (DTx) are effective and safe, but not being prescribed

pharmaphorum

In a new episode of the pharmaphorum podcast, host Nicole Raleigh welcomes Joel Morse, CEO and co-founder of Curavit Clinical Research, and Andy Molnar, CEO of the Digital Therapeutics Alliance (DTA), for a discussion on why it is that digital therapeutics (DTx) are effective and safe, but not being prescribed.

114
114
article thumbnail

Opinion: There’s a public health crisis lurking in our data: the Census option ‘some other race’

STAT

According to the 2020 Census, the second most common race in America , after white, is “Some other race,” an option chosen by an astonishing one out of seven people. The nationwide failure to accurately measure the variety of races and ethnicities that make up the U.S. population makes underrepresented groups invisible in public health data, resulting in policies informed by inadequate or misleading information.

111
111
article thumbnail

Big pharma places big bets on antibody-drug conjugates

pharmaphorum

Big pharma companies like Pfizer are making significant investments in antibody-drug conjugates, a promising class of therapies. This article explores the growing interest and recent developments, including FDA approvals and the potential impact on the pharmaceutical industry.

FDA 114
article thumbnail

Study Investigates Amiodarone As a Potential Toxin Inhibitor for Clostridioides difficile Infections

Pharmacy Times

Amiodarone also provides pan-variant protection against toxins, a potentially growing area of research in C. difficile infection treatment.

121
121
article thumbnail

STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors

STAT

Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are enveloping the Pharmalot campus, where the official mascots are bounding about the grounds and the short person has departed for a challenging apprenticeship. As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own busy agendas.

110
110
article thumbnail

After missing out on FDA voucher, bluebird quickly raises funds to support gene therapy launches

Fierce Pharma

Despite bluebird bio winning a recent FDA nod for its muc | Bluebird's FDA approval for sickle cell disease gene therapy Lyfgenia left something to be desired because the agency rejected a request for a priority review voucher. Without that voucher, bluebird is moving fast to try to fund its launches.

FDA 110
article thumbnail

Interrupting Immune-Suppresser Treatment Could Boost Effects of COVID-19 Booster

Pharmacy Times

The antibody response among those that interrupted treatment was doubled at 4 weeks and 1.5 times greater at 26 weeks.

article thumbnail

Deloitte: Improving health equity in 2024 is a top-10 goal for most execs

Fierce Healthcare

More than 80% of C-suite executives from healthcare and life sciences organizations see improved health equity as a top-10 goal for 2024, a recent report by Deloitte found. | The report also found that nearly 50% of respondents expect to increase equity investments next year.

108
108
article thumbnail

Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023 

Pharmaceutical Technology

Pharmaceutical Technology outlines some of the biggest US Food and Drug Administration (FDA) drug approvals announced in 2023 that are set to make an impact in the coming years.

FDA 105
article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. Since only about 20 percent of the world’s population is lucky enough to live in areas where reliable refrigeration is available, 1 the remaining majority live with

Vaccines 106
article thumbnail

Is Advil or Tylenol better for a headache?

The Checkup by Singlecare

If you’re like most people, you probably have a medicine cabinet full of over-the-counter pain relief options: Advil (ibuprofen) , Tylenol (acetaminophen) , or Aleve (naproxen). You might turn to Tylenol for a fever and Advil or Aleve for arthritis pain. But what about when a headache strikes? Is one of these painkillers superior to the other? “Even though Advil and Tylenol are two of the most common OTC [over-the-counter] pain medications, many people don’t know that they work differently and h

Dosage 105
article thumbnail

Bioanalytical labs need to reimagine data to streamline their operations

pharmaphorum

In the ever-evolving field of bioanalytical labs, reimagining data processes can greatly streamline operations during various trial phases of drug development.

106
106
article thumbnail

Addressing the evolving needs of pharma for CDx development

Fierce Pharma

Partnerships in healthcare have never been more important. | Agilent Technologies discusses the importance of working with pharmaceutical companies to drive medical innovation and improve patient outcomes, helping to speed up the process of bringing the right treatments to the right patients at the right time.

article thumbnail

Still Thriving After 160 Years: Hieber’s Pharmacy in Pennsylvania

Pharmacy Times

Rosemary Sassic-Mihalko, PharmD, is the fourth owner and first female owner of pittsburgh’s oldest pharmacy

123
123